## **OPTIMA HEALTH PLAN**

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If information provided is NOT</u> complete, correct, or legible, authorization will be delayed.

**Drug Requested:** Palynziq<sup>™</sup> (pegvaliase-pqpz) **Injection** 

<b>DRUG INFORMATION:</b> Complete all information below or authorization will be delayed.		
Dru	g Form/Strength:	
	ng Schedule: Length of Therapy:	
Diag	gnosis: ICD Code, if applicable:	
	INICAL CRITERIA. Check below <u>ALL</u> that apply. <u>ALL</u> criteria <u>must</u> be met for approval. <u>ALL</u> umentation, including lab results and/or chart notes (when required), <u>must</u> be provided or request will be ied.	
IN	ITIAL APPROVAL - 6 MONTHS	
	Patient must be at least 18 years old	
	Patient must have a diagnosis of phenylketonuria (chart notes must be attached for documentation)	
	Provider must be a metabolic geneticist or physician knowledgeable in the management of phenylketonuria	
	Baseline current phenylalanine levels must be >600 $\mu$ mol/L <u>OR</u> average phenylalanine levels must have been >600 $\mu$ mol/L for the last 6 months on existing management (lab results from within the last 30 days must be attached)	
	Initial dose must be administered under the supervision of a healthcare provider and auto-injectable epinephrine must be prescribed	
	Medication will <b>NOT</b> be used in combination with Kuvan <sup>®</sup>	
	Patient must $\underline{\text{NOT}}$ have taken Kuvan <sup>®</sup> within 14 days of last phenylalanine lab $\underline{\textbf{or}}$ within 14 days of initial therapy with Palynziq <sup>TM</sup>	
	<b>ONTINUED APPROVAL - 6 MONTHS: ALL</b> criteria below <b>MUST</b> be met for approval. <b>ALL</b> umentation, including lab results and/or chart notes ( <b>when required</b> ), <b>must</b> be provided or request will be ied.	
	Patient must be at least 18 years old	
	Patient must have a diagnosis of phenylketonuria (chart notes must be attached for documentation)	
	Provider must be a metabolic geneticist or physician knowledgeable in the management of phenylketonuria	
	Phenylalanine levels must have decreased by at least 20% from baseline $\underline{OR}$ phenylalanine blood levels must have decreased to $\leq 600~\mu mol/L$ and continue to be maintained at those levels while on maintenance therapy (labs completed within the last 30 days must be attached)	
	Medication will <b>NOT</b> be used in combination with Kuvan®	

(continued on next page)

## Medication being provided by a Specialty Pharmacy - PropriumRx

\*\* Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. \*\*

\*Previous Therapies will be verified through pharmacy paid claims or submitted chart notes.\*

D. J. J. M.	
Patient Name:	
Member Optima #:	
Prescriber Name:	
Prescriber Signature:	
Office Contact Name:	
Phone Number:	Fax Number:
DEA OR NPI #:	

<sup>\*</sup>Approved by Pharmacy and Therapeutics Committee: 7/19/2018 REVISED/UPDATED: 9/29/2018; (Reformatted) 5/22/2019;